A clinical textbook

Hepatology 2018

2. Hepatitis B

Raphael Mohr, Christoph Boesecke and Jan-Christian Wasmuth

Introduction

Approximately one third of the world’s population has serological evidence of past or present infection with the hepatitis B virus (HBV). Despite the availability of HBV vaccines, the global prevalence of chronic HBV infection is estimated to be 3.7% (Lok 2016). Of the 350–400 million people that are HBV surface antigen (HBsAg) carriers, approximately one million die of HBV-related causes annually (Goldstein 2005, WHO 2012).

Since the discovery of HBV by Blumberg in 1965, progress has been impressive, with the availability of vaccines in the 1980s and the development of potent antiviral drugs two decades later. Nevertheless, the global burden of chronic HBV remains substantial.

There is a wide range of HBV prevalence rates in different parts of the world (from 0.1% up to 20%). Low prevalence areas (<2%) represent 12% of the global population and include Western Europe, the United States and Canada, Australia and New Zealand. In these regions, the lifetime risk of infection is less than 20%. Intermediate prevalence is defined as 2% to 7%, with a lifetime risk of infection of 20–60% and includes the Mediterranean countries, Japan, Central Asia, the Middle East, and Latin and South America, representing about 43% of the global population. High prevalence areas (≥8%) include Southeast Asia, China, and sub-Saharan Africa, where a lifetime likelihood of infection is greater than 60%. The diverse prevalence rates are probably related to differences in age at infection, which correlates with the risk of chronicity. The progression rate from acute to chronic HBV infection decreases with age. Approximately 90% of infections acquired perinatally will progress compared to 5% or less for adult infections (Stevens 1975, Wasley 2008, Pan 2016).

The incidence of new HBV infections has decreased in most high-income countries, most likely due to the implementation of vaccination strategies (Rantala 2008, Leroy 2015). However, exact data is difficult to generate as many cases remain undetected due to the asymptomatic nature of the infection. In Germany, 2374 cases of acute HBV were documented in 2014, corresponding to an incidence rate of 0.9 per 100,000 inhabitants (RKI 2015). In 1997 there were 6135 documented cases of acute HBV. Likewise, the incidence of acute HBV in the United States has decreased considerably in the last two decades (Wasley 2008, CDC 2012). Although estimates are difficult due to a continuously growing migration from high to low prevalence areas (Belongia 2008), a further drop in prevalence is expected due to the implementation of vaccination programmes. In Germany, 88% of all children starting school in 2013 were fully vaccinated against HBV, with a trend toward increasing coverage (Poethko-Muller 2007, RKI 2015).

Although the incidence of acute HBV infection is decreasing in most countries, overall HBV-related complications are still on the rise (Gomaa 2008, Hatzakis 2011, Zhang 2013). Reasons for this increase may be the delay of vaccination effects and the improved diagnosis rate of HBV cases. When looking at the age-adjusted rate ratios of HBV-related HCC incidence, a continuous decline can be observed following the launch of vaccination programmes. Recently published results of a large population-based controlled trial in Chinese newborns show that HCC incidence was significantly lower in the vaccinated group compared to the control group, with a hazard ratio of 0.16 (Qu 2014).

Transmission

The predominance of transmission modes varies considerably in different geographic areas. For example, in Western Europe (a low prevalence area), the main routes are unprotected sexual intercourse and intravenous drug use. In sub-Saharan Africa (a high prevalence area), perinatal infection is the predominant mode of transmission. Horizontal transmission, particularly in early childhood, is regarded as the major route of transmission in intermediate prevalence areas.

Sexual transmission

Sexual transmission of HBV in people who are unvaccinated largely occurs among heterosexual men or women who either have multiple sex partners or contact with sex workers, or among men who have sex with men (MSM). In low prevalence areas, sexual transmission is the major route of transmission. In the United States, heterosexual contacts amount up to 40% of newly diagnosed HBV infections, MSM approximately 25% (Wasley 2008), in Germany 23% and 32% respectively (RKI 2015). Comparatively high rates of HIV/HBV coinfections are observed in German MSM, as less than half of HIV positive patients are vaccinated against HBV (Jansen 2015). However, as noted above, infection in adulthood leads to chronic hepatitis in less than 5% of cases. Measures to prevent sexual HBV transmission are vaccination – especially of risk groups – and safer sex practices.

Percutaneous inoculation

Percutaneous inoculation seems to be an effective mode of HBV transmission, with an estimated risk as up to 30% in individuals without post-exposure prophylaxis (PEP) or adequate vaccination (Deisenhammer 2006, Hofmann 2002). The most important percutaneous transmission route is sharing syringes and needles by people who inject drugs (PWID), representing about 15% of newly diagnosed HBV infections in low prevalence areas such as Europe and the United States (Wasley 2008). Sharing razors or toothbrushes are other potential ways of percutaneous transmission, although absolute risk remains unknown. In addition, practices like acupuncture, tattooing, and body piercing have been associated with transmission of HBV. Public health education and the use of disposable needles or equipment are important methods of prevention.

Perinatal transmission

Perinatal transmission is the major route of HBV transmission in many parts of the world, and an important factor in maintaining the reservoir of the infection, particularly in high prevalence areas. In the absence of prophylaxis, chronic HBV infection will develop in 80 to 90% of infants born to mothers who are positive for HBV e antigen (HBeAg) (Lee 2006). Neonatal vaccination has demonstrated high efficacy, indicating that transmission mostly occurs at or shortly before birth. On the other hand, cesarean section seems less protective than for other vertically transmitted diseases such as HIV.

The risk of transmission from mother to infant is related to the mother’s HBV replicative rate. There seems to be a direct correlation between maternal HBV DNA levels and the likelihood of transmission. In mothers with highly replicating HBV the risk of transmission may be up to 85 or 90%. This risk steadily drops at lower HBV DNA levels (Burk 1994, Zhang 2012). Some studies report that perinatal transmission is rare if the mother has HBV DNA <105 log copies/mL (Li 2004).

All women should be tested for HBsAg at the first prenatal visit and this should be repeated later in pregnancy if appropriate (CDC 2011). Newborns born to HBV positive mothers can be effectively protected by passive-active immunisation (>90% protection rate) (Del Canho 1997, Dienstag 2008, WHO 2015). HBV immunoglobulin for passive immunisation should be given as early as possible (within 12 hours), but can be given up to seven days after birth if replicative HBV infection of the mother is detected later. Active immunisation follows a standard regimen and is given at three time points (10 µg at day 0, month 1, and month 6). However, immunoprophylaxis fails in 10 to 30% of infants born to mothers with an HBV DNA level greater than 106 log copies/mL (Zou 2012). In a recent cohort study, no HBV infection was observed in infants born to HBeAg negative mothers who received HBV vaccine, independently of immunoglobulin administration (Zhang 2014).

Anti-HBV treatment of the mother with nucleoside analogues may be considered, especially in mothers with high HBV DNA levels. The use of telbivudine, lamivudine, and tenofovir appears to be safe in pregnancy with no increased adverse maternal or fetal outcome (Brown 2016). Adefovir and entecavir are not recommended in pregnancy (Cornberg 2011). Treatment of mothers with telbivudine prevented almost all cases of vertical transmission compared to a vertical transmission rate of about 10% in the arm receiving only active-passive immunisation (Han 2011, Wu 2014). Tenofovir starting from 30 weeks of gestation until postpartum week 4 combined with immunoprophylaxis demonstrated significantly lower transmission rates in HBeAg positive mothers compared to immunoprophylaxis alone (Pan 2016). Lamivudine seems to be another safe, low cost and equally effective option to prevent vertical transmission in highly viraemic HBV-infected pregnant women (Jackson 2014, Zhang 2014). A recently published meta-analysis showed that the use of any antiviral therapy reduced mother-to-child transmission, as defined by infant HBV surface antigen seropositivity (risk ratio = 0.3, 95% CI 0.2–0.4) or infant HBV DNA seropositivity (risk ratio 5 0.3, 95% CI 0.2–0.5) at 6–12 months (Brown 2016).

As mentioned earlier, cesarean section should not be performed routinely. If the child is vaccinated, (s)he may be breastfed (Hill 2002). Taking lamivudine or tenofovir during breastfeeding results in lower exposure to drugs than due to in utero exposure during pregnancy and thus does not support contraindicating their use during breastfeeding (Ehrhardt 2014).

Horizontal transmission

Horizontal transmission includes household, intrafamiliar and child-to-child transmission via minor breaks in the skin or mucous membranes. At least 50% of infections in children cannot be accounted for by mother-to-infant transmission and, in many endemic regions, before the introduction of neonatal vaccination, the prevalence peaked in children 7 to 14 years of age (Papatheodoridis 2008). HBV remains viable outside the human body for a prolonged period and is infectious in the environment for at least 7 days (Lok 2007). Although HBV DNA has been detected in various body fluids of HBV carriers, there is no firm evidence of HBV transmission via body fluids other than blood.

In one study, family members of inactive HBsAg carriers had a higher HBsAg positivity rate than the general population over a 10-year period. Despite negative HBV DNA levels, transmission risk was not negligible in these patients, and horizontal transmission seems to be independent of the HBV DNA level (Demirturk 2014).

Blood transfusion

Blood donors are routinely screened for HBV surface antigen (HBsAg). Therefore incidence of transfusion-related HBV has significantly decreased. The risk of acquiring post-transfusion HBV depends on factors like prevalence and donor testing strategies. In low prevalence areas it is estimated to be one to four per million blood components transfused (Dodd 2000, Polizzotto 2008). In high prevalence areas it is considerably higher (around 1 in 20,000) (Shang 2007, Vermeulen 2011).

There are different strategies for donor screening. Most countries use HBsAg screening of donors. Others, including the United States, use both HBsAg and anti-HBc. Routine screening of anti-HBc remains controversial, as the specificity is low and patients with cleared hepatitis have to be excluded. Screening of pooled blood samples or even individual samples may be further improved by nucleic acid amplification techniques. However, this is an issue of continuous debate due to relatively low risk reduction and associated costs.

Nosocomial infection

Nosocomial infection can occur from patient to patient, from patient to health care worker and vice versa. HBV is considered the most commonly transmitted blood-borne virus in the healthcare setting. Despite implementation of prevention strategies (including the use of disposable needles and equipment, sterilisation of surgical instruments, and vaccination of healthcare workers) documented cases of nosocomial infections occur (Williams 2004, Amini-Bavil-Olyaee 2012). However, the exact risk of nosocomial infection is unknown. The numbers of cases reported from this route is likely to be underestimated as many infections might be asymptomatic and only a fraction of exposed patients are recalled for testing.

The incidence of HBV infection in health care workers is lower than in the general population due to routine vaccination (Duseja 2002, Mahoney 1997). Therefore, transmission from healthcare workers to patients is rare, while the risk of transmission from an HBV positive patient to a health care worker seems to be higher.

Healthcare workers who are HBV positive are not generally prohibited from working. HBeAg negative healthcare workers are not considered to be infectious, whereas HBeAg positive healthcare workers should wear double gloves and not perform certain activities, to be defined on an individual basis (Gunson 2003, Cornberg 2011). However, cases of transmission from HBsAg positive, HBeAg negative surgeons to their patients have been reported (Teams 1997) and a precore stop codon mutation was found responsible for HBeAg non-expression despite active HBV replication (Borzooy 2015). Therefore, HBV DNA testing has been implemented in some settings, although this may not always be reliable due to fluctuating levels of HBV DNA. In most high-income countries, guidelines for HBV positive healthcare workers have been established and should be consulted (Cornberg 2011).

The risk of transmission of HBV through sharps injuries (when the patient is HBeAg positive) is estimated as 1:3 (Riddell 2015). Despite HBV being highly infectious, only 24 cases of occupational transmission by sharps injuries have been reported in Germany during 2013 (RKI 2015). This low number probably relates to the high percentage of healthcare workers who are immunised against HBV. Based on vaccination history, previous response to vaccination, type of exposure, and the HBV status of the source patient a vaccine can be given shortly after exposure either as the first dose of a primary course or as a booster. The additional use of immunoglobulin aims to provide passive immunity if the source patient is known to be at high risk of HBV infection and the recipient has not been previously adequately immunised or is a known non-responder to the vaccine.

Organ transplantation

Transmission of HBV infection has been reported after transplantation of extrahepatic organs from HBsAg positive donors (e.g., kidney, cornea) (Dickson 1997). Organ donors are therefore routinely screened for HBsAg. The role of anti-HBc is controversial, as it is in screening of blood donors. Reasons are the possibility of false positive results, the potential loss of up to 5% of donors even in low endemic areas, and the uncertainty about the infectivity of organs, especially extrahepatic organs, from donors who have isolated anti-HBc (Dickson 1997). Although an increased risk of HBV infection for the recipient of anti-HBc positive organs has been postulated, no donor-derived HBV transmission has been observed in a recent case series of anti-HBc positive donors (Horan 2014, Niu 2014). Evidence exists that patients who have recovered from HBV may benefit from preemptive antiviral therapy in the case of profound immunosuppression (e.g., chemotherapy involving monoclonal antibodies such as rituximab or immunosuppressive treatment) because of the risks associated with a form of HBV reactivation referred to as reverse seroconversion (Di Bisceglie 2014).

Postexposure prophylaxis

In case of exposure to HBV in any of the circumstances mentioned above, post-exposure prophylaxis is recommended for all non-vaccinated persons. A passive-active immunisation is recommended. The first dose of passive and active immunisation should be given as early as possible. 12 hours after the exposure is usually considered the latest time point for effective post-exposure prophylaxis. One dose of HBV-immunoglobulin (HBIG) should be administered at the same time, if the source is known to be HBsAg positive. The other two doses of vaccine should be administered after 4 and 12–24 weeks.

Vaccinated individuals with a documented response do not need post-exposure prophylaxis. Individuals who have had no post-vaccination testing should be tested for anti-HBs titre as soon as possible. If this is not possible, or the anti-HBs titre is insufficient (<100 IU/L), they will require a second course of vaccination.

Individuals who are documented non-responders will require two doses of HBIG given one month apart.

Natural history and clinical manifestations

The spectrum of clinical manifestations of HBV infection varies in both acute and chronic disease. During the acute phase, manifestations range from subclinical or anicteric hepatitis to icteric hepatitis, and in some cases fulminant hepatitis. During the chronic phase, manifestations range from an asymptomatic carrier state to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Extrahepatic manifestations can occur in both acute and chronic infection.

Acute hepatitis

After HBV infection, the incubation period lasts from one to four months. A prodromal phase may appear before acute hepatitis develops. During this period a serum sickness-like syndrome may develop. This syndrome manifests with fever, skin rash, arthralgia and arthritis. It will usually cease with the onset of hepatitis. At least 70% of patients then have subclinical or anicteric hepatitis, while less than 30% will develop icteric hepatitis. The most prominent clinical symptoms of hepatitis are right upper quadrant discomfort, nausea, jaundice and other unspecific constitutional symptoms. In case of coinfection with other hepatitis viruses or other underlying liver disease the clinical course may be more severe. Symptoms – including jaundice – generally disappear after one to three months, but some patients have prolonged fatigue even after normalisation of serum aminotransferase concentrations.

During the acute phase, alanine and aspartate aminotransferase levels (ALT and AST) may increase to 1000–2000 IU/L. ALT is typically higher than AST. Bilirubin levels may be normal in a substantial portion of patients. In patients who recover, normalisation of serum aminotransferases usually occurs within one to four months. Persistent elevation of serum ALT for more than six months indicates progression to chronic hepatitis.

The rate of progression from acute to chronic HBV is primarily determined by the age at infection (Ganem 2004, McMahon 1985). In adult-acquired infection the chronicity rate is 5% or less, whereas it is higher if acquired at younger ages. Approximately 90% for perinatal acquired infection (up to six months of age) become chonic, but this rate decreases to 20–60% for infections acquired between the age of six months and five years (Caredda 1989, Smedile 1982).

For decades it was assumed that the virus is cleared in patients who recover from acute HBV. However, even in patients positive for anti-HBs and anti-HBc, HBV DNA may persist lifelong in the form of covalently closed circular DNA (cccDNA) and this latent infection maintains the T cell response that enables viral control (Yotsuyanagi 1998, Guner 2011, Gerlich 2013, Zhong 2014). It is now accepted that complete eradication rarely occurs. This is important, as immunosuppression can lead to reactivation of the virus, e.g., after organ transplant or during chemotherapy (Di Bisceglie 2014).

Fulminant hepatic failure is rare, only occurring in approximately 0.1–0.5% of patients. Reasons and risk factors for fulminant HBV are not well understood (Garfein 2004). This may correlate with substance use or coinfections with other viruses. Fulminant HBV is believed to be due to massive immune-mediated lysis of infected hepatocytes. This is why many patients with fulminant HBV have no evidence of HBV replication at presentation.

Antiviral treatment of patients with acute HBV usually is not recommended (Cornberg 2011). In adults, the likelihood of fulminant HBV is less than 1%, and the likelihood of progression to chronic HBV is less than 5%. Therefore, treatment of acute HBV is mainly supportive in the majority of patients. Antiviral treatment with HBV polymerase inhibitors can be considered in certain subsets of patients, e.g., patients with a severe or prolonged course of HBV, patients coinfected with other hepatitis viruses or underlying liver diseases, patients with immunosuppression, or patients with fulminant liver failure undergoing liver-transplantation (Kondili 2004, Tillmann 2006).

In addition, patient contacts should be tested for HBV and vaccinated if appropriate.

Chronic hepatitis

In adult-acquired infection, HBV chronicity is 5% or lower, as mentioned earlier. In perinatally acquired infection it is estimated to be approximately 90%, and 20–50% for infections between the age of one and five years (Ganem 2004, McMahon 1985). Most patients will not have a history of acute hepatitis.

Most patients with chronic HBV (CHB) are clinically asymptomatic. Some may have nonspecific symptoms such as fatigue. In most instances, significant clinical symptoms will develop only if liver disease progresses to decompensated cirrhosis. In addition, extrahepatic manifestations may cause symptoms.

Accordingly, a physical exam will be normal in most instances. In advanced liver disease there may be clinical signs of chronic liver disease including splenomegaly, spider angioma, caput medusae, palmar erythema, testicular atrophy, gynecomastia. In patients with decompensated cirrhosis, jaundice, ascites, peripheral edema, and encephalopathy may be present.

Laboratory testing shows mild to moderate elevation in serum AST and ALT in most patients, whereas normal transaminases occur rarely. During exacerbation, serum ALT concentration may be as high as 50 times the upper limit of normal. Alpha-fetoprotein concentrations correlate with disease activity. In exacerbations of HBV, concentrations as high as 1000 ng/mL may be seen.

The natural course of CHB infection is determined by the interplay of viral replication and the host immune response. Other factors that may play a role in the progression of HBV-related liver disease include gender, alcohol consumption, and concomitant infection with other hepatitis viruses. The outcome of CHB infection depends upon the severity of liver disease at the time HBV replication is arrested. Liver fibrosis is potentially reversible once HBV replication is controlled.

There are several typical patterns of CHB acquired in adult or later childhood:

First, infection with a wildtype HBV variant: There is the classic necroinflammatory state with high HBV DNA, HBeAg positive, high ALT and active liver disease.

Second, infection with a precore mutant, which has become much more common than wildtype virus in the recent years. After infection with a precore mutant HBeAg is negative despite considerable HBV DNA replication and elevated ALT.

Third, a low or non-replicative phase, where serum ALT is normal, HBeAg is negative and anti-HBe antibodies are usually present and HBV DNA is low or not detectable. This status is characterised by partial immune control of the HBV infection.

In perinatally acquired chronic HBV infection there are three different states: (i) an immune tolerance phase, (ii) an immune clearance phase, and (iii) a late non-replicative phase.

The immune tolerance phase, which usually lasts 10 to 30 years, is characterised by high levels of HBV replication, as manifested by the presence of HBeAg and high levels of HBV DNA in serum. However, there is no evidence of active liver disease as seen by normal serum ALT concentrations and minimal changes in liver biopsy. It is thought that this lack of liver disease despite high levels of HBV replication is due to immune tolerance to HBV (Dienstag 2008), although the exact mechanisms are unknown. This phenomenon of immune tolerance is believed to be the most important reason for the poor response to interferon therapy in HBeAg positive patients with normal ALT levels. During this phase there is a very low rate of spontaneous HBeAg clearance. It is estimated that the rate of spontaneous HBeAg clearance is only 15% after 20 years of infection.

During the second to third decade, the immune tolerant phase may convert to immune clearance. The spontaneous HBeAg clearance rate increases – estimated to be 10 to 20% annually. If HBeAg seroconversion occurs, exacerbations of hepatitis with abrupt increases in serum ALT are very often observed. These exacerbations follow an increase in HBV DNA and might be due to a sudden increase in immune-mediated lysis of infected hepatocytes. Most often there are no clinical symptoms during exacerbation, and ALT increase is only detected by routine examinations. Some patients may develop symptoms mimicking acute hepatitis. Anti-HBc IgM titres and alpha-fetoprotein may increase. If such patients are not known to be HBV-infected, misdiagnosis of acute HBV can be made. HBeAg seroconversion and HBV DNA clearance from serum is not always achieved after exacerbation. In these patients, recurrent exacerbation with intermittent disappearance of serum HBV DNA with or without HBeAg loss may occur. The non-replicative phase is usually characterised by the absence of HBV DNA and normalisation of serum ALT, like in adult chronic HBV.

Very few patients with chronic HBV infection become HBsAg negative in the natural course of infection. The annual rate of HBsAg clearance has been estimated to be less than 2% in patients from high-income countries and even lower (0.1–0.8%) in patients of Asian origin (Liaw 1991) following an accelerated decrease in HBsAg levels during the three years before HBsAg seroclearance (Chen 2011). If loss of HBsAg occurs, prognosis is considered favourable. However, clearance of HBsAg does not exclude development of cirrhosis or hepatocellular carcinoma in some patients, although the exact rate of these complications is unknown. This phenomenon is thought to be linked to the fact that HBV DNA may still be present in hepatocytes despite HBsAg loss.

Prognosis and survival

There is a wide variation in clinical outcome and prognosis of chronic HBV infection. Recent data showed that in France about three-quarters of patients with chronic HBV who progressed to a liver-related complication had an additional liver-related risk factor (Mallet 2016). The risk of progression appears to be higher if immune activation occurs. Moreover, increased all-cause mortality in HBsAg positive patients was observed (Montuclard 2015). The lifetime risk of liver-related death has been estimated to be 40 to 50% for men and 15% for women.

Estimated five-year rates of progression (Fattovich 2008) are:

Survival rates are:

Viral replication

Survival is consistently worse in patients with signs of substantial viral replication compared to patients who are HBV DNA negative or who have very low HBV DNA levels. During the natural course of chronic infection, the appearance of the precore stop codon and basal core promoter variants initiates the seroconversion from HBeAg to anti-HBe positivity and leads to the awakening of the immune response. However, variants may emerge and lead to HBeAg negative CHB with high viraemia levels. The prevalence of HBeAg negative CHB has been increasing over the last decades. Acute exacerbations accompanied by high viral replication, elevated ALT levels and histological activity are a common feature of HBeAg negative CHB leading to cirrhosis and HCC much faster than in HBeAg positive CHB patients (Alexopoulou 2014, Papatheodoridis 2001).

In recent years, HBV DNA levels have been linked to disease progression and has replaced HBeAg positivity as a marker for disease activity (Chen 2006). This is true both for progression to cirrhosis and risk of HCC. Therefore, most treatment guidelines are based on HBV viraemia. A reasonable cut-off to distinguish patients with a low compared to high risk of progression and indication for antiviral treatment is 104 log copies/mL (corresponding to approximately 2 x 103 IU/mL) (Cornberg 2011), although other cut-offs may be used.

Duration of viral replication is linked with the risk of development of cirrhosis and HCC. As necroinflammation may persist longer in patients with a prolonged replicative phase, the risk of disease progression is elevated. Conversely, even in patients with decompensated cirrhosis, suppression of HBV replication and delayed HBsAg clearance can improve liver disease (Fung 2008).

Alcohol use

Heavy alcohol use is associated with faster HBV progression to liver injury and an elevated risk of developing cirrhosis and HCC (Bedogni 2008, Marcellin 2008). Survival is reduced compared to heavy alcohol users who are HBV negative. However, there is no clear evidence that heavy alcohol use is associated with an enhanced risk of chronic HBV infection, although prevalence of HBV is estimated to be fourfold higher than in controls (Laskus 1992) with variation among regions and cohorts (Rosman 1996).

Hepatitis C (HCV) coinfection

In patients with HBV/HCV coinfection, HCV usually predominates. This may lead to lower levels of transaminases and HBV DNA (Jardi 2001). The rate of HBsAg seroconversion even appears to be increased, as there is a well-known entity of occult HBV infection (patients with negative HBsAg but detectable serum HBV DNA) in patients with chronic HCV (Cacciola 1999, Torbenson 2002, Raimondo 2005). Despite lower aminotransferases and HBV DNA levels, liver damage is worse in most cases. The risks of severe hepatitis and fulminant hepatic failure seem to be elevated if both infections occur simultaneously regardless of whether it is an acute coinfection of HBV and HCV or acute HCV in chronic HBV (Liaw 2004).

Hepatitis D coinfection

An acute HBV/HDV coinfection tends to be more severe than an acute HBV infection alone. It is more likely to result in fulminant hepatitis. If HDV superinfection occurs in patients with CHB, HDV usually dominates, and HBV replication is suppressed (Jardi 2001). Severity of liver disease is worse and progression to cirrhosis is accelerated (Fattovich 2000, Grabowski 2010, Heidrich 2012) (see Chapter 10).

Extrahepatic manifestations

The two major extrahepatic complications of chronic HBV are polyarteritis nodosa and renal impairment due to glomerular disease. They occur in up to 10% of patients with chronic HBV and are thought to be mediated by circulating immune complexes (Han 2004).

Polyarteritis nodosa

The clinical manifestations are similar to those in patients with polyarteritis who are HBV negative. There may be some clinical benefit to antiviral therapy.

Nephropathy/Glomerulonephritis

HBV can induce both membranous nephropathy and, less often, membranoproliferative glomerulonephritis. Most cases occur in children. The clinical hallmark is proteinuria. In contrast to polyarteritis nodosa, there is no significant benefit of antiviral treatment.

For further details, please refer to extrahepatic manifestations in chapter 15.

References

Alexopoulou A, Karayiannis P. HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection. World J Gastroenterol. 2014;20:7644-52.

Amini-Bavil-Olyaee S, Maes P, Van Ranst M, Pourkarim MR. Providing strong evidence of nosocomial outbreak of hepatitis B virus infection. J Hosp Infect. 2012; 80(3):269-70.

Bedogni G, Miglioli L, Masutti F, et al. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Am J Gastroenterol 2008;103:2248-53.

Belongia EA, Costa J, Gareen IF, et al. NIH Consensus Development Statement on Management of Hepatitis B: Draft. NIH Consens State Sci Statements 2008;25:1-29.

Blanco NB, Probst A, Da Costa VW, et al. Impact of a Nurse Vaccination Program on Hepatitis B Immunity in a Swiss HIV Clinic. J Acquir Immune Defic Syndr. 2011;58:472-4.

Borzooy Z, Jazayeri SM, Mirshafiey A, et al. Identification of occult hepatitis B virus (HBV) infection and viral antigens in healthcare workers who presented low to moderate levels of anti-HBs after HBV vaccination. Germs. 2015;5:134-40.

Brown RS Jr, McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology. 2016;63:319-33.

Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994;170:1418-23.

Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-6.

CDC Department of Health & Human Services, Centers for Disease Control and Prevention, Division of Viral Hepatitis. Hepatitis B. General information. J Pract Nurs 2010;60:5-6.

CDC Centers for Disease Control and Prevention (CDC). Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data – United States. MMWR 2011;60:410-3.

CDC Centers for Disease Control and Prevention (CDC). Viral Hepatitis Surveillance – United States, 2010; Reported number of acute hepatitis B cases — United States, 2000-2010, http://www.cdc.gov/hepatitis/Statistics/2010Surveillance/Slide3.1.htm.

Caredda F, Antinori S, Pastecchia C, et al. Incidence of hepatitis delta virus infection in acute HBsAg negative hepatitis. J Infect Dis. 1989;159:977–9.

Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006;295:65-73.

Chen YC, Jeng WJ, Chu CM, Liaw YF. Decreasing Levels of Hepatitis B Surface Antigen Predict Hepatitis B Surface Antigen Seroclearance in Patients With Inactive Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2012;10:297-302.

Cornberg M, Protzer U, Petersen J, et al. Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol 2011;49:871-930.

Deisenhammer S, Radon K, Nowak D, Reichert J. Needlestick injuries during medical training. J Hosp Infect. 2006;63:263-7.

Demirturk N, Demirdal T. Inactıve hepatitis B surface antigen carriers and intrafamilial tramsmission: results of a 10-year study. Clin Mol Hepatol. 2014;20:56-60.

Di Bisceglie AM, Lok AS, Martin P, et al. Recent FDA warnings on hepatitis B reactivation with immune-suppressing and anti-cancer drugs: Just the tip of the iceberg? Hepatology. 2015;61:703-11.

Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997;113:1668-74.

Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500.

Dodd RY. Current viral risks of blood and blood products. Ann Med 2000;32:469-74.

Duseja A, Arora L, Masih B, et al. Hepatitis B and C virus-prevalence and prevention in health care workers. Trop Gastroenterol 2002;23:125-6.

Ehrhardt S, Xie C, Guo N, et al. Breastfeeding While Taking Lamivudine or Tenofovir Disoproxil Fumarate: A Review of the Evidence. Clin Infect Dis. 2015;60:275-8.

European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2012;57:167-185

Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52.

Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol 2008;23:1182-92.

Ganem D, Prince AM. Hepatitis B virus infection – natural history and clinical consequences. N Engl J Med 2004;350:1118-29.

Garfein RS, Bower WA, Loney CM, et al. Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology 2004;40:865-73.

Gerlich. Medical Virology of Hepatitis B: how it began and where we are now. Virol J. 2013;10: 239.

Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005;34:1329-39.

Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008;14:4300-8.

Grabowski J, Wedemeyer H. Hepatitis delta: immunopathogenesis and clinical challenges. Dig Dis. 2010;28:133-8.

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization, March 2015 (http://appswho .int/ iris/bitstream/ 10665/ 154590/ 1/9789241549059_eng .pdf?ua=1).

Guner R, Karahocagil M, Buyukberber M, et al. Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg negative chronic hepatitis B infection. Eur J Gastroenterol Hepatol. 2011;23:1185-91.

Gunson RN, Shouval D, Roggendorf M, et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol. 2003 27(3):213-30.

Han SH. Extrahepatic manifestations of chronic hepatitis B. Clin Liver Dis 2004;8:403-18.

Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat. 2011 Sep;18 Suppl 1:1-16.

Heidrich B, Manns MP, Wedemeyer H. Treatment Options for Hepatitis Delta Virus Infection. Curr Infect Dis Rep. 2012 Dec 15.

Hepatitis B fact sheet no. 204. Geneva: World Health Organization, July 2015 (http://www .who .int/ mediacentre/factsheets/ fs204/ en/ ).

Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002;99:1049-52.

Hofmann F, Kralj N, Beie M. Needle stick injuries in health care – frequency, causes und preventive strategies. Gesundheitswesen. 2002;64:259-66.

Horan JL, Stout JE, Alexander BD. Hepatitis B core antibody-positive donors in cardiac transplantation: a single-center experience. Transpl Infect Dis. 2014;16:859-63.

Jackson V, Ferguson W, Kelleher TB, et al. Lamivudine treatment and outcome in pregnant women with high hepatitis B viral loads. Eur J Clin Microbiol Infect Dis. 2015;34:619-23.

Jansen K, Thamm M, Bock CT, et al. High Prevalence and High Incidence of Coinfection with Hepatitis B, Hepatitis C, and Syphilis and Low Rate of Effective Vaccination against Hepatitis B in HIV-Positive Men Who Have Sex with Men with Known Date of HIV Seroconversion in Germany. PLoS One. 2015;10:e0142515.

Jardí R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001;34:404-10.

Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat 2004;11:427-31.

Laskus T, Radkowski M, Lupa E, Horban A, Cianciara J, Slusarczyk J. Prevalence of markers of hepatitis viruses in out-patient alcoholics. J Hepatol 1992;15:174-78.

Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen positive mothers. Cochrane Database Syst Rev 2006; 2: CD004790.

Leroy V, Asselah T. Universal hepatitis B vaccination: The only way to eliminate hepatocellular carcinoma? J Hepatol. 2015;63:1303-5.

Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991;13:627-31.

Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004;126:1024-29.

Li XM, Shi MF, Yang YB, et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol 2004;10:3215-17.

Mahoney FJ, Stewart K, Hu H, Coleman P, Alter MJ. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch Intern Med 1997;157:2601-5.

Lok AS, McMahon BJ, Brown RS Jr, el tal. Antiviral Therapy for Chronic Hepatitis B Viral Infection in Adults: A Systematic Reviewand Meta-Analysis. Hepatology. 2016;63:284-306.

Mallet V, Hamed K, Schwarzinger M. Prognosis of patients with chronic hepatitis B in France (2008-2013): A nationwide, observational and hospital-based study. J Hepatol. 2016. pii: S0168-8278(16)30642-0.

Marcellin P, Pequignot F, Delarocque-Astagneau E, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008;48:200-7.

McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.

Montuclard C, Hamza S, Rollot F, et al. Causes of death in people with chronic HBV infection: A population-based cohort study. J Hepatol. 2015;62:1265-71.

Niu Y, Chen X, Feng L, et al. Anti-HBc-positive/HBsAg negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts. Clin Res Hepatol Gastroenterol. 2014;38:475-80.

Pan CQ, Duan Z, Dai E, et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. N Engl J Med. 2016;374:2324-34.

Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat. 2001;8:311-21.

Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg negative chronic hepatitis B virus infection. J Viral Hepat. 2008;15:434–41.

Poethko-Muller C, Kuhnert R, Schlaud M. [Vaccination coverage and predictors for vaccination level. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007;50:851-62.

Polizzotto MN, Wood EM, Ingham H, Keller AJ. Reducing the risk of transfusion-transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006. Transfusion 2008;48:55-63.

Qu C, Chen T, Fan C, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med. 2014;30:11.

Raimondo G, Cacciamo G, Saitta C. Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol. 2005;4:100-6.

Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe – a review. Euro Surveill 2008;13:pii18880.

Riddell A, Kennedy I, Tong CY. Management of sharps injuries in the healthcare setting. BMJ. 2015;351:h3733.

RKI. Virushepatitis B und D im Jahre 2014. Epidemiologisches Bulletin 2015;29:271-288.

RKI. Hepatitis C: RKI-Ratgeber Infektionskrankheiten. Epidemiologisches Bulletin 2004;17:141.

Rosman AS, Waraich A, Galvin K, Casiano J, Paronetto F, Lieber CS. Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am J Gastroenterol 1996;91:498-505.

Shang G, Seed CR, Wang F, Nie D, Farrugia A. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. Transfusion 2007;47:529-39.

Smedile A, Farci P, Verme G, et al. In uence of delta infection on severity of hepatitis B. Lancet. 1982;2:945–7.

Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292:771-4.

Teams. Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. The Incident Investigation Teams and others. N Engl J Med 1997;336:178-84.

Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006;13:256-63.

Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002:2:479-86.

Vermeulen M, Dickens C, Lelie N, et al. Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion. 2011

Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis – United States, 2006. MMWR Surveill Summ 2008;57:1-24.

World Health Organization. Hepatitis B Fact sheet No. 204, 2012.

Williams IT, Perz JF, Bell BP. Viral hepatitis transmission in ambulatory health care settings. Clin Infect Dis 2004;38:1592-8.

Wu Q, Huang H, Sun X, et al. Telbivudine Prevents Vertical Transmission of Hepatitis B Virus from Women High Viral Loads: A Prospective Long-term Study. Clin Gastroenterol Hepatol. 2015;13:1170-6.

Yotsuyanagi H, Yasuda K, Lino S, et al. Persistent viraemia after recovery from self-limited acute hepatitis B. Hepatology 1998;27:1377-82.

Zhang H, Pan CQ, Pang Q, et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60:468-76.

Zhang L, Gui XE, Teter C, et al. Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine. Vaccine. 2014;32:6091-7.

Zhang Y, Zhang H, Elizabeth A, Liu XQ. Epidemiology of hepatitis B and associated liver diseases in china. Chin Med Sci J. 2013 ;27(4):243-8.

Zhang RL, Wang MY, Chen QY, et al. Study on the risk factors related vertical transmission of HBV positive couples to their infant. Zhonghua Liu Xing Bing Xue Za Zhi. 2012 ;33(12):1283-7.

Zhong Y, Hu S, Xu C, et al. A novel method for detection of HBVcccDNA in hepatocytes using rolling circle amplification combined with in situ PCR. BMC Infect Dis. 2014;14:608.

Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg positive mothers. J Viral Hepat 2012; 19: e18-25.

Hepatology 2018

Home
Start/Foreword 
Table of contents
Contributing authors
Free PDF Download

The Editors

Stefan Mauss
Thomas Berg
Juergen Rockstroh
Christoph Sarrazin
Heiner Wedemeyer

English language and style

Simon Collins

Design

Schaafkopp.de

Privacy policy

© 2018 by Mauss, et al.